How will the generic ANDA submission for Sitagliptin affect Merck?
Generic competitor challenges market exclusivity of Sitagliptin tablets A generic competitor has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for Sitagliptin Tablets USP in 25 mg, 50 mg, and 100 mg strengths. This submission targets the U.S. market, where the innovator product, Januvia, is marketed by Merck. The generic entry is timed as the relevant U.S. phosphate salt patent is scheduled to expire in November 2026, after which the market will open to generic competition. This development introduces a direct and long-term revenue threat to Merck's flagship product line.
- Effect
- Strong negative
- How direct
- Stated in the reporting
- When
- Over the long term
- The story
- No new developments lately
How it reaches Merck
-
Morepen Laboratories Limited submitted its first Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for Sitagliptin Tablets USP in 25 mg, 50 mg, and 100 mg strengths. This filing marks the company's entry into finished dosage regulatory submissions for the U.S. market. Morepen estimates a 24 to 36-month timeline from submission to potential approval and commercial supply.
The full event2independent outlets -
Morepen Laboratories Ltd submitted the ANDA to the U.S. FDA on September 25, 2026, for Sitagliptin Tablets USP in three strengths: 25 mg, 50 mg, and 100 mg. This filing targets the U.S. market, where the innovator product, Januvia, is marketed by Merck. The generic entry is strategically timed ahead of the relevant U.S. phosphate salt patent expiration in November 2026.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- thehindubusinessline.com Monday
-
public company in Indonesia
Everything about Merck
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The ANDA was submitted to the U.S. Food and Drug Administration on September 25, 2026.thehindubusinessline.com
- The generic application covers Sitagliptin Tablets USP in 25 mg, 50 mg, and 100 mg strengths.thehindubusinessline.com, equitybulls.com
- The relevant U.S. phosphate salt patent is set to expire in November 2026.thehindubusinessline.com, equitybulls.com
- Januvia, the branded version, recorded global sales of approximately $1.604 billion in 2025.thehindubusinessline.com, equitybulls.com
Why it matters
For Merck, the generic challenge to Sitagliptin is critical as it relates to Januvia, the company's branded product. The successful generic entry into the U.S. market, which is a major sales territory, will introduce price competition and erode the market share of the innovator product. This forces Merck to accelerate its pipeline diversification and explore alternative growth avenues to mitigate the impact of patent expiration.
The generic entry is not immediate but is projected to take between 24 to 36 months from submission to reach potential approval and commercial supply. This timeline allows the generic competitor to establish a presence while the innovator product is still generating significant revenue. The successful navigation of the FDA review process and patent clearance will determine the ultimate success of the generic challenge.
What we don't know yet
- How will the FDA review process affect the timeline for generic approval?
- What is the market acceptance of the generic Sitagliptin tablets in the U.S.?
Is this still moving?
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
What would change this answer
Reporting
- thehindubusinessline.comMonday
- equitybulls.comMonday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. It explains possible effects; it is not investment advice.